1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2025, Issue 1
  5. Article
Volume 2025, Issue 1
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Cardiovascular disease (CVD) affects 500 million people globally, with mortality over 20 million. In the UK, the financial burden is estimated to be approximately £54 billion. Consequently, Lp(a) has been incorporated as an additional biomarker for cardiovascular risk stratification. It is used as a superior marker over the traditional marker LDL-C.

This was a single-centre retrospective study conducted at Hampshire Hospital NHS Foundation Trust spanning 16 months (September 2022–January 2024). Lp(a) results were retrieved from the laboratory database and assessed for trends. The distribution of Lp(a) results was also compared with the values outlined in the HEART UK consensus statement (2019). Additionally, demographic characteristics such as age, sex, medical history, and lifestyle factors were collected. Personal details, including names, addresses, and phone numbers, were anonymised to ensure confidentiality. A total of 192 patients were included in the study. These patients were referred for a lipid panel by lipid specialists (172), GP surgeries (10), cardiologists (5), unspecified consultants (3) and endocrinologists (2). All patients were over 18 years of age. They were attending the clinic and had been screened for dyslipidaemia and high cardiovascular risk, including conditions such as familial hypercholesterolaemia, renal dysfunction, and those on antilipid therapy.

The demography included 99 (52%) females and 93 (48%) males. The chronological age (mean ± SD) was 61.17 ± 13.18 for females and 53.91 ± 12.84 for males ( < 0.001). Additionally, the Lp(a) values were 126.50 ± 118.92 and 135.33 ± 99.59 ( < 0.01) for females and males, respectively. The analysed samples were categorised as normal ( ≤ 32 nmol/L) and abnormal (>32 nmol/L) concentrations of Lp(a), with normal results observed in 104 patients and abnormal results in 88 patients: Lp(a) ≤ 32 nmol/L (54%) versus >32 nmol/L (46%),  < 0.0001. According to the CVD risk groupings established by HEART UK, 54%, 12%, 18%, 15% and 1% of the patients had Lp(a) values of 12.2 ± 7.5, 52.20 ± 16.42, 147.14 ± 36.64, 291.71 ± 62.49, and 471.50 ± 28.99 nmol/L, classified as normal, minor risk, moderate risk, high risk, and very high risk, respectively.

This study provided evidence supporting the inclusion of Lp(a) as an extra component in lipid profile testing. Elevated levels of Lp(a) are associated with an increased risk of CVD, which may be more significant than the risk posed by LDL-C. Incorporating Lp(a) as a routine biomarker in real-world clinical practice would accurately stratify cardiovascular risk, particularly for patients with elevated Lp(a) concentrations, and could potentially be a more significant risk than LDL-C in individuals at high risk for CVD, especially for those ≥ 50 years of age.

© 2025 Gbaa, Bolodeoku, Morris, Whitehead, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.16
2025-03-17
2025-04-10
The full text of this item is not currently available.

References

  1. Lindstrom M, DeCleene N, Dorsey H. Summary of global burden of disease study methods. J Am Coll Cardiol. 2022; 80:(25):2372–425. doi: 10.1016/j.jacc.2022.11.001 .
     [Google Scholar]
  2. British Heart Foundation. UK factsheet; 2024 [cited 19 Jun 2024]. Available from: https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf .
  3. Collins B, Bandosz P, Guzman-Castillo M, Pearson-Stuttard J, Stoye G, McCauley J, et al. What will the cardiovascular disease slowdown cost? Modelling the impact of CVD trends on dementia, disability, and economic costs in England and Wales from 2020–2029. PLoS One. 2022 Jun 29; 17:(6):e0268766. doi: 10.1371/journal.pone.0268766 .
     [Google Scholar]
  4. Cheema KM, Dicks E, Pearson J, Samani NJ. Long-term trends in the epidemiology of cardiovascular diseases in the UK: Insights from the British Heart Foundation Statistical Compendium. Cardiovasc Res. 2022 Jul 27; 118:(10):2267–80. doi: 10.1093/cvr/cvac053 .
     [Google Scholar]
  5. Hsu H-Y, Tsa M-C, Yeh T-L, Hsu L-Y, Hwang L-C, Chien K-L. Association of baseline as well as change in lipid levels with the risk of cardiovascular diseases and all-cause deaths. Sci Rep. 2021 Apr 1; 11:(1):7381. doi: 10.1038/s41598-021-86336-6 .
     [Google Scholar]
  6. Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato CPellicori F, et al. Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health. 2023 Sep 6; 20:18:6721. doi: 10.3390/ijerph20186721 .
     [Google Scholar]
  7. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016 Aug; 57:(8):1339–1359. doi: 10.1194/jlr.R067314 .
     [Google Scholar]
  8. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML. Marcovina SM, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018 Jan 16; 71:(2):177–92. doi: 10.1016/j.jacc.2017.11.014 .
     [Google Scholar]
  9. Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017 Mar; 12:(Suppl 1):31–7. doi: 10.1007/s11789-017-0084-1 .
     [Google Scholar]
  10. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ. Berglund L, Dweck MR, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14; 43:(39):3925–46. doi: 10.1093/eurheartj/ehac361 .
     [Google Scholar]
  11. Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, et al.. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022 Oct; 9:(2):e002060. doi: 10.1136/openhrt-2022-002060 .
     [Google Scholar]
  12. Langsted A, Nordestgaard BG. Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?. Curr Opin Lipidol. 2020; 31:(3):125–31. doi: 10.1097/mol.0000000000000681 .
     [Google Scholar]
  13. Garg PK, Guan W, Karger AB, Steffen BT, Budoff MJ, Tsai MY. Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: the multi-ethnic study of atherosclerosis. J Cardiovasc Comput Tomogr. 2021 Mar–Apr; 15:(2):154–60. doi: 10.1016/j.jcct.2020.06.002 .
     [Google Scholar]
  14. Markus MRP, Ittermann T, Schipf S, Bahls M, Nauck M, Völzke H, et al.. Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021 Aug 18; 20:(1):168. doi: 10.1186/s12933-021-01363-x .
     [Google Scholar]
  15. Aljawini N, Aldakhil LO, Habib SS. High-risk lipoprotein(a) levels in Saudi Women and its relationship to menopause and adiposity. Nutrients. 2023 Jan 30; 15:(3):693. doi: 10.3390/nu15030693 .
     [Google Scholar]
  16. Seo Y-H, Shi H-Y. Relationship between lipoprotein(a) and dyslipidemia in the elderly over 60 years. Korean J Clin Lab Sci. 2022 Jun 30; 54:(2):95–102. doi: 10.15324/kjcls.2022.54.2.95 .
     [Google Scholar]
  17. Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower lipoprotein(a). Atherosclerosis. 2022 May;349:110–22. doi: 10.1016/j.atherosclerosis.2022.04.020 .
     [Google Scholar]
  18. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E et al.. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020 Jan 16; 382:(3):244–55. doi: 10.1056/NEJMoa1905239 .
     [Google Scholar]
  19. Koren MJ, Moriarty PM, Neutel J, Baum SJ, Hernandez-Illas M, Weintraub, HS, et al.. Abstract 13951: safety, tolerability and efficacy of single-dose Amg 890, a Novel Sirna Targeting Lp(a), in healthy subjects and subjects with elevated Lp(a). Circulation. 2020 Nov 12; 142:(Suppl_3). doi: 10.1161/circ.142.suppl_3.13951 .
     [Google Scholar]
  20. Kotani K, Banach M. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J Thoracic Dis. 2017 Jan; 9:(1):E78–82. doi: 10.21037/jtd.2017.01.40 .
     [Google Scholar]
  21. Sahebkar A, Watts GF. New Therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013 Dec; 27:(6):559–67. doi: 10.1007/s10557-013-6479-4 .
     [Google Scholar]
/content/journals/10.5339/qmj.2025.16
Loading
Assessment of the trends in lipoprotein(a) concentration in high-risk cardiovascular patients: A retrospective study
Qatar Medical Journal 2025, 16 (2025); https://doi.org/10.5339/qmj.2025.16
/content/journals/10.5339/qmj.2025.16
/content/journals/10.5339/qmj.2025.16
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): ApoE, cardiovascular disease, LDL-C, Lipoprotein(a), Lp(a) and LPA

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error